Compare VENUS REMEDIES with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SUVEN LIFESCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SUVEN LIFESCIENCES VENUS REMEDIES/
SUVEN LIFESCIENCES
 
P/E (TTM) x -1.5 19.5 - View Chart
P/BV x 0.1 3.9 2.7% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 VENUS REMEDIES   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
SUVEN LIFESCIENCES
Mar-19
VENUS REMEDIES/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs126338 37.3%   
Low Rs61169 36.1%   
Sales per share (Unadj.) Rs301.852.1 578.9%  
Earnings per share (Unadj.) Rs-24.96.8 -364.1%  
Cash flow per share (Unadj.) Rs2.58.6 29.7%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs293.365.3 449.2%  
Shares outstanding (eoy) m12.34127.28 9.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.9 6.4%   
Avg P/E ratio x-3.837.1 -10.1%  
P/CF ratio (eoy) x36.729.6 124.2%  
Price / Book Value ratio x0.33.9 8.2%  
Dividend payout %022.0 0.0%   
Avg Mkt Cap Rs m1,15432,272 3.6%   
No. of employees `0000.91.1 85.5%   
Total wages/salary Rs m393661 59.5%   
Avg. sales/employee Rs Th4,026.16,132.2 65.7%   
Avg. wages/employee Rs Th425.0611.1 69.5%   
Avg. net profit/employee Rs Th-331.8803.5 -41.3%   
INCOME DATA
Net Sales Rs m3,7246,635 56.1%  
Other income Rs m23242 9.3%   
Total revenues Rs m3,7476,877 54.5%   
Gross profit Rs m3951,604 24.6%  
Depreciation Rs m338221 152.8%   
Interest Rs m35438 939.8%   
Profit before tax Rs m-2751,587 -17.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32718 4.4%   
Profit after tax Rs m-307869 -35.3%  
Gross profit margin %10.624.2 43.8%  
Effective tax rate %-11.545.2 -25.4%   
Net profit margin %-8.213.1 -62.9%  
BALANCE SHEET DATA
Current assets Rs m2,6386,232 42.3%   
Current liabilities Rs m2,3051,490 154.7%   
Net working cap to sales %8.971.5 12.5%  
Current ratio x1.14.2 27.4%  
Inventory Days Days13586 156.7%  
Debtors Days Days4683 56.1%  
Net fixed assets Rs m4,8714,043 120.5%   
Share capital Rs m123127 96.9%   
"Free" reserves Rs m3,4968,183 42.7%   
Net worth Rs m3,6198,310 43.6%   
Long term debt Rs m1,37418 7,721.3%   
Total assets Rs m7,50910,389 72.3%  
Interest coverage x0.243.1 0.5%   
Debt to equity ratio x0.40 17,729.2%  
Sales to assets ratio x0.50.6 77.7%   
Return on assets %0.68.7 7.2%  
Return on equity %-8.510.5 -81.1%  
Return on capital %1.619.5 8.1%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m05,622 0.0%   
Fx outflow Rs m5171,799 28.7%   
Net fx Rs m-5173,822 -13.5%   
CASH FLOW
From Operations Rs m514356 144.7%  
From Investments Rs m-123-279 44.2%  
From Financial Activity Rs m-387-225 172.0%  
Net Cashflow Rs m4-148 -2.8%  

Share Holding

Indian Promoters % 32.9 63.4 51.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 0.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 36.5 181.9%  
Shareholders   20,121 37,287 54.0%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ASTRAZENECA PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS